Skip Navigation

This Article
Right arrow Print PDF (3914K)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Commercial Re-use Guidelines
for Open Access NAR Content
Google Scholar
Right arrow Articles by Bergan, R.
Right arrow Articles by Neckers, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bergan, R.
Right arrow Articles by Neckers, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nucleic Acids Research, 1994, Vol. 22, No. 11 2150-2154
© 1994

ENZYMOLOGY

Aptameric inhibition of p210bcr-abl tyrosine kinase autophosphorylation by oligodeoxynucleotides of defined sequence and backbone structure

Raymond Bergan*, Yvette Connell, Brigid Fahmy, Edward Kyle and Len Neckers

Clinical Pharmacology Branch, National Cancer Institute, National Institutes of Health Bethesda, MD 20892, USA

*To whom correspondence should be addressed

Received November 24, 1993. Revised April 25, 1994. Accepted April 25, 1994.

Protein tyrosine kinases play key roles in cellular physiology. Specific inhibitors of these enzymes are important laboratory tools and may prove to be novel therapeutic agents. In this report we describe a new class of tyrosine kinase inhibitor, synthetic oligodeoxynucleotides (ODNs). An ODN is described which specifically inhibits p210bcr-abl tyrosine kinase autophosphorylation in vitro with a K1 of 0.5 µM. Inhibition is non-competitive with respect to ATP. The effects upon inhibitory activity of ODN structure modifications are described. The inhibition described is not mediated by classical antisense mechanisms and represents an example of the recently recognized aptameric properties of ODNs.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
A. A. Fisher, D. Ye, D. S. Sergueev, M. H. Fisher, B. R. Shaw, and R. L. Juliano
Evaluating the Specificity of Antisense Oligonucleotide Conjugates. A DNA ARRAY ANALYSIS
J. Biol. Chem., June 14, 2002; 277(25): 22980 - 22984.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. A. James and I. Gibson
The Therapeutic Potential of Ribozymes
Blood, January 15, 1998; 91(2): 371 - 382.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
J.L. Vaerman, P. Moureau, F. Deldime, P. Lewalle, C. Lammineur, F. Morschhauser, and P. Martiat
Antisense Oligodeoxyribonucleotides Suppress Hematologic Cell Growth Through Stepwise Release of Deoxyribonucleotides
Blood, July 1, 1997; 90(1): 331 - 339.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. M. Fennewald and R. F. Rando
Inhibition of High Affinity Basic Fibroblast Growth Factor Binding by Oligonucleotides
J. Biol. Chem., September 15, 1995; 270(37): 21718 - 21721.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.